The Chinese baby formula maker's deal for Australia's Swisse Wellness shows SOEs have rivals for overseas M&A targets. But some wonder if Biostime is punching above its weight.

Chinese infant formula manufacturer is looking to make its debut international bond offering to partially finance the repurchase of its outstanding convertible debt.

Chinese baby formula milk continues to be a winner with investors.

Biostime signed a $450 million bridge facility to cover part of its $992.4 million acquistion of Australia's Swisse Wellness Group.

Chinese state-owned enterprises’ acquisition of Australia’s third-largest vitamins firm by sales reflects the country’s hunger for food safety – but not at any price.

Foreign companies and local players are looking to expand in China's underdeveloped healthcare sector. But will they enjoy the returns they expect without an overhaul?

The return of the convertible bond market this year suggests that Asia’s controlling shareholders see share prices approaching full value.

Buying Australia’s leading health supplement brand matches Fosun’s global ambitions — and could also help the target boost its China sales.

The Chinese pharmaceutical firm offers $238 million to take Vitaco private, in the latest example of China’s huge interest in clean and green food products.

Generic drug manufacturer takes advantage of rising order books for Indian high-yield deals to price significantly through many brokers' fair value estimates.